Nevertheless, p53 is found mutated in approximately 85% of CRC cases, and TP53-mutated colon cancer cells tend to be more resistant to many anticancer drugs, including 5-FU and oxaliplatin, compared to TP53 wild-type cells [74,101]. Here, TP53 is linked to malignant colon neoplasm.